Contact
Please use this form to send email to PR contact of this press release:
Soligenix, Inc. (NASDAQ: SNGX) Developing Treatments for Multiple Cancers, Vaccine Candidates (Ebola, Sudan, & Marburg)
TO:
SNGX
Soligenix, Inc.
+1 609-538-8200